Braidwell LP Has $47.94 Million Stock Holdings in Krystal Biotech, Inc. $KRYS

Braidwell LP trimmed its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 29.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 128,975 shares of the company’s stock after selling 53,450 shares during the period. Krystal Biotech makes up about 1.8% of Braidwell LP’s holdings, making the stock its 16th largest holding. Braidwell LP’s holdings in Krystal Biotech were worth $47,936,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Silvant Capital Management LLC bought a new position in Krystal Biotech in the 2nd quarter worth $30,000. Western Wealth Management LLC bought a new stake in Krystal Biotech during the first quarter valued at about $34,000. Greenline Wealth Management LLC bought a new stake in Krystal Biotech during the fourth quarter valued at about $34,000. Danske Bank A S acquired a new stake in shares of Krystal Biotech in the third quarter valued at about $35,000. Finally, UMB Bank n.a. increased its stake in shares of Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Krystal Biotech

In other news, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the transaction, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares of the company’s stock, valued at $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 13.10% of the stock is owned by company insiders.

Krystal Biotech Stock Up 1.5%

Krystal Biotech stock opened at $369.23 on Thursday. The business has a 50 day moving average price of $349.86 and a two-hundred day moving average price of $306.35. Krystal Biotech, Inc. has a 12 month low of $136.73 and a 12 month high of $382.54. The stock has a market cap of $10.93 billion, a price-to-earnings ratio of 46.27 and a beta of 0.54.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping the consensus estimate of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, analysts expect that Krystal Biotech, Inc. will post 7.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on KRYS shares. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. TD Cowen increased their price objective on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Jefferies Financial Group restated a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. Finally, Citigroup boosted their target price on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Krystal Biotech has an average rating of “Moderate Buy” and an average price target of $365.40.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.